Developing a nanotechnology-enabled glaucoma device

An affectionate mature couple embracing outdoors, enjoying a moment of love and tranquility.

VisiPlate is designed to treat open-angle glaucoma

VisiPlate is an investigational implant designed to lower intraocular pressure in patients with open-angle glaucoma

A graphical representation of an eyeball with a close-up inset showing hexagonal microcomponents from VisiPlate.

A next-generation aqueous shunt

Multichannel – VisiPlate is designed to lower eye pressure through a network of microchannels that control aqueous drainage from the anterior chamber.

A single, finger upright against a white home background with a VisiPlate on top.

A next generation aqueous shunt

Ultrathin – VisiPlate is several times thinner than a human hair. VisiPlate leverages an ultrathin material with the goal of achieving greater patient comfort and aesthetics.

Close-up view of a material with a hexagonal pattern, with VisiPlate showing a magnified texture detail.

A next-generation aqueous shunt

Innovative Composition – VisiPlate is composed of alumina and Parylene-C with the goal of minimizing foreign body response and reducing the risk of scarring.

Building at the cutting edge

Avisi leverages MEMS (Micro-Electro-Mechanical Systems) manufacturing and utilizes high-performance equipment and advanced micro-fabrication manufacturing techniques. This development of small and advanced medical devices is intended to be at the forefront of minimally-invasive treatments.

Avisi’s proprietary material technology features an ultrathin, freestanding material, invented at the University of Pennsylvania.

Avisi’s scientific advisors hail from world-class institutions and bring together a diverse array of expertise. Drawing from leading universities, renowned research centers, and top-tier industry leaders, their experience helps guide Avisi.

Glaucoma is the "silent thief of sight"

Glaucoma is the leading cause of irreversible blindness. It was estimated to affect 4 million in the US and 103 million people world-wide. The overall prevalence within the US is 2.1% and 3.54% globally. It is estimated that 3.36 million people 40 years and older in the US have open-angle glaucoma. This disease is on the rise and expected to reach 111.8 million globally by 2040.

A blurred view of the highway leading home through a vehicle's rearview mirror.

Glaucoma is a group of eye diseases that damage the optic nerve and result in vision loss. The two most common types are primary open-angle glaucoma (POAG) and primary angle-closure glaucoma (PACG). 90% of US glaucoma patients have POAG. There are typically no early warning signs or symptoms for POAG which is why it is known as the “silent thief of sight.” Consequently, routine eye exams are critical to diagnosis. No cure for glaucoma has been discovered yet and the only clinically proven way to modify disease progression is to lower the pressure inside the eye. Current treatments cannot reverse vision loss but are designed to slow disease progression, thereby preventing further vision loss.

Five cheerful senior friends posing together outdoors near their home.

Everyone is at risk for developing glaucoma, but certain groups have a higher risk. All people over the age of 60 are 6 times more likely to develop a type of glaucoma. Those with diabetes are twice as more likely to develop a type of glaucoma. Prevalence also varies with race. People of African-Caribbean and African American descent over the age of 40 are 8 times more likely to develop POAG.

A modern hospital corridor with a row of chairs and a daylight lighting system is designed to offer patients and visitors optimal comfort.

Today, the national economic impact of glaucoma takes up the majority of $5.8 billion spent on treatment and management of optic nerve disorders. Ten million doctor visits occur each year for glaucoma resulting in $2.5 billion in annual healthcare costs. The burden of these costs on the US healthcare system is expected to significantly rise as the number of patients increases. Only 50% of people with glaucoma are diagnosed. The other 50% are unaware of their disease. Additionally, it is projected that the number of people affected by glaucoma will increase two folds by 2050.

Avisi in the news

Avisi Technologies featured at LSI’s 2024 US Emerging Medtech Summit. Dr. Catherine Mohr delivers the keynote presentation.

Avisi Technologies Featured at LSI’s 2024 US Emerging Medtech Summit in Keynote Presentation

Summary of Avisi Involvement as Presenting Company 2024 and 2023 Panel Representation Avisi Technologies returned to the 2024 US Emerging Medtech Summit with updates about the development of VisiPlate, a nanotechnology-enabled aqueous shunt for the treatment of glaucoma. Avisi generated buzz in the Life Science Intelligence (LSI) community by announcing exclusive clinical data, showing promising […]

Illustration of a doctor examining a patient's eye for glaucoma, representing the work of the South African Glaucoma Society and advancements in glaucoma treatment.

VisiPlate® Aqueous Shunt Safety and Effectiveness data from VITA Clinical Trial to be presented at the 2024 South Africa Glaucoma Society Annual Congress

Interim trial results demonstrate the safety and effectiveness of VisiPlate® as a standalone treatment for primary open-angle glaucoma.   REDWOOD CITY, Calif., (May 14, 2024) – Avisi Technologies, Inc., an ophthalmic-focused medical device manufacturer, is developing a portfolio of ophthalmic treatments based on a novel metamaterial technology. Avisi’s flagship product, VisiPlate, is a nanotechnology-enabled implant […]

Avisi Technologies, Junkosha Award, Innovation

Avisi Technologies Shortlisted for Junkosha Innovator of the Year Award

Avisi Technologies has been shortlisted for Junkosha’s second-year Innovator of the Year Award program. This year had a tremendous number of applicants with Avisi Technologies being 1 of the 11 shortlisted to impress the panel of expert judges chosen for their vast industry experience in medical devices. The winning company will be awarded a $25,000 […]

See All News

Supported by

Accanto Partners Logo
Good Growth Capital Logo
Life Sciences Greenhouse Investments Logo
MedVenture Partners
Mountain State Capital Logo
Skip to content